This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: G51.2 | Special Copayment Reduction: V167 | 5 years |
| B. Synonyms | Melkersson syndrome, Melkersson-Rosenthal syndrome |
| C. Adult onset | Onset is most common in childhood to adolescence, but first onset in adulthood also occurs; moderate likelihood of first presentation in adulthood |
| 1. History | First described by Melkersson in 1928; fissured tongue added by Rosenthal in 1931; triad completed by Kussmaul in 1949 |
| 2. Causes | Unknown cause; multifactorial, including infection, allergy, genetic predisposition, autoimmunity and association with Crohn disease |
| 3. Genetics | Presumed autosomal dominant, family history 28%; no consistent single causative gene identified, associations with HLA-A*02, DRB1*11 and DQB1*03 reported |
| 4. General epidemiology | Estimated prevalence 0.08–1%, female predominance, age at onset 10s–30s; the complete triad appears in only about 25% of all cases |
| 5. Pathophysiology | Non-caseating granuloma formation → lymphatic stasis → recurrent orofacial edema; facial nerve palsy due to perineural infiltration |
| 6. Symptoms | Recurrent facial palsy, orofacial edema, fissured tongue (plicated tongue); monosymptomatic and oligosymptomatic forms are more common than the complete triad |
| 7. Signs | Non-pitting, elastic lip enlargement, facial palsy graded by House-Brackmann (HB), confirmation of fissured tongue, possible limb and orbital edema |
| 8. Screening | Confirmation of the clinical triad, facial nerve function assessment (HB grading), confirmation of recurrence pattern, history-taking for accompanying gastrointestinal symptoms |
| 9. Diagnosis | Lip tissue biopsy (confirmation of non-caseating granuloma), facial nerve MRI, ACE and IBD differentiation, endoscopy to exclude Crohn disease |
| 10. Treatment | Intralesional triamcinolone, systemic corticosteroids, clofazimine, infliximab/adalimumab (refractory); short-term steroids for facial palsy |
| 11. Prognosis | Non-fatal but with repeated recurrence; incomplete recovery from facial palsy, permanent lip enlargement, reduced quality of life; possible coexisting Crohn disease |
| 12. Prevention | Avoidance of recurrence triggers (infection, dental procedures, stress); when Crohn disease coexists, treatment of the underlying disease helps suppress recurrence |
| 13. References | Kanerva M et al. Acta Otolaryngol 2008 and 9 other papers |
The history of Melkersson-Rosenthal syndrome (MRS) begins in 1928, when the Swedish physician Ernst Gustaf Melkersson first reported a patient with recurrent facial nerve palsy accompanied by orofacial edema. Melkersson suggested at the time that these symptoms might be an independent clinical entity distinct from idiopathic recurrent facial palsy (recurrent Bell palsy). His initial description focused on the combination of facial edema and nerve palsy.
In 1931, the Czechoslovak neurologist Curt Rosenthal independently described fissured/plicated tongue (lingua plicata) as the third component of this syndrome, laying the foundation for the "triad" known today. The name Melkersson-Rosenthal syndrome, combining the names of the two physicians, was given after that. In 1949, the German physician Kussmaul formally organized these three features into a single syndrome.
Until the mid-20th century, this syndrome was known only as a very rare and unusual neurologic and dermatologic disease, but it was gradually recognized that single- or dual-symptom forms (monosymptomatic forms) are much more common than the complete triad. In the 1950s–70s, its association with cheilitis granulomatosa (Miescher type) began to be discussed, and the concept that the two conditions are monosymptomatic variants of MRS became established.
Since the 1980s–90s, the association between MRS and Crohn disease has been established through numerous case reports and long-term follow-up studies. The histopathologic findings of the two diseases (non-caseating granulomas) are similar, and prospective studies have reported a higher risk of inflammatory bowel disease in patients with MRS. Recently, TNF inhibitors (infliximab, adalimumab) have been used effectively in refractory MRS, and molecular-level understanding of autoimmune and granuloma-forming mechanisms has deepened.
The exact cause of Melkersson-Rosenthal syndrome has not yet been identified. The hypotheses proposed to date are multifactorial, and genetic predisposition, immune abnormalities, infection, allergic reactions and autonomic nervous system abnormalities are presumed to be involved in combination. No single causative gene or specific pathogen has been established as the decisive cause.
Infection hypotheses include an exaggerated immune response to viruses (herpes simplex virus, Epstein-Barr virus), bacteria (Borrelia, Mycobacterium tuberculosis, Chlamydia) and oral bacterial antigens. In fact, attacks are triggered in some patients after upper respiratory infections or dental procedures. Allergens mentioned include benzoate preservatives, food dyes, nickel and cobalt. The proportion of patients with positive contact allergy patch tests is higher than in the general population.
Evidence supporting an autoimmune mechanism includes positive anti-SS-A and anti-RNP autoantibodies, elevated serum angiotensin-converting enzyme (ACE) and HLA associations. Histopathology shows CD4+ T cell-predominant granulomatous inflammation. In particular, the shared histopathologic findings (non-caseating granulomas) and clinical association with Crohn disease suggest that the two diseases may belong to the same immunopathologic spectrum. Associations with sarcoidosis and Hodgkin lymphoma have also been reported rarely.
As for genetic background, an autosomal dominant inheritance pattern is observed in some families, but complete penetrance is low. Genome-wide association studies (GWAS) have been conducted only to a limited extent, and there are reports that variants in IBD-related genes (NOD2, IL23R, etc.) are associated with the risk of MRS. In conclusion, MRS is understood as a granulomatous neuro-oral disease that arises when the immune response is overactivated by environmental triggers (infection, allergens, stress) in genetically predisposed individuals.
The mode of inheritance of MRS is presumed to be autosomal dominant, but penetrance is low and expressivity is highly variable, so diverse phenotypes such as the complete triad, oligosymptomatic and monosymptomatic forms coexist even within a family. A family history is reported in about 28% of all patients. If one parent is affected, the risk to a child is theoretically 50%, but the actual clinical expression rate is lower.
In HLA association studies, an increased frequency of the HLA-A*02, HLA-DRB1*11 and HLA-DQB1*03 alleles and a decreased frequency of HLA-A*01, HLA-DRB1*04, HLA-DRB1*07 and HLA-DQB1*02 were observed in patients with MRS. This suggests that certain HLA haplotypes may increase the risk of MRS or be protective. However, no single HLA allele is diagnostically specific.
Genetic variants shared with Crohn disease are also being studied. The R702W, G908R and Leu1007fsinsC variants of the NOD2/CARD15 gene are established risk variants in Crohn disease, and these variants have also been identified in some patients with MRS. Variants in intestinal immune regulatory genes such as IL-23R, IL-10 and ATG16L1 are also being explored for an association with MRS. This supports the view that MRS and Crohn disease form a spectrum of granulomatous intestinal and extraintestinal immune diseases with a common genetic basis.
To date, no MRS-specific causative gene has been found, and no genetic diagnostic panel has been clinically established. Genetic counseling is therefore performed empirically, integrating family history, clinical phenotype and family history of Crohn disease. When there is a family history, observation of children for early onset of lip edema, facial palsy and fissured tongue is recommended.
The exact prevalence of MRS is unclear, but depending on the literature it is estimated at 0.08–1% of the total population. It is classified as a rare disease, and the actual frequency may be underreported. The complete triad (facial palsy + lip enlargement + fissured tongue) appears in only about 25% of all patients with MRS; the rest have monosymptomatic or oligosymptomatic forms showing only one or two features. Therefore, waiting for the complete triad in clinical practice can greatly delay diagnosis.
By sex, women are reported to be affected about 1.5–2 times more often than men. Age at onset ranges from childhood to old age, but typical onset is in the 10s–30s, with a median age at onset around the 20s. It is not uncommon in children and adolescents, in whom lip enlargement often appears as a single symptom. Racial differences are unclear, but relatively more cases are reported in Northern European and European-descent populations.
Fissured tongue is a common anatomic variant present asymptomatically in about 5–11% of the general population, so fissured tongue alone is insufficient grounds for a diagnosis of MRS. There are reports that MRS is diagnosed in about 10–15% of patients who first present with recurrent facial nerve palsy (recurrent Bell palsy). MRS or cheilitis granulomatosa accompanies about 0.5–5% of patients with Crohn disease, and conversely, the risk of Crohn disease in patients with MRS is higher than in the general population.
In Korea it is registered under rare disease Special Copayment Reduction code V167 and requires renewal every 5 years. Because recurrent facial palsy is often the clue to diagnosis, collaboration among neurology, otolaryngology and oral and maxillofacial surgery is important. A delay of several years on average until diagnosis is commonly reported.
The core pathophysiology of MRS is non-caseating granulomatous inflammation occurring in facial tissues, particularly the lips and oral mucosa. The granulomas consist of CD4+ T lymphocytes, macrophages, epithelioid histiocytes and multinucleated giant cells, and are histopathologically similar to sarcoid granulomas. Perilymphatic inflammation accompanying this granuloma formation causes lymphatic stasis, and with repeated episodes fibrosis gradually progresses, so that lip enlargement becomes irreversibly fixed.
The mechanism of facial nerve palsy is nerve compression by granulomas and edema within or around the facial canal, and perineural inflammatory infiltration. When edema occurs in the narrow space between the labyrinthine and vertical segments of the facial nerve, nerve conduction is blocked. When repeated nerve injury and incomplete recovery accumulate, permanent facial palsy may remain.
A Th1-biased immune response has been proposed as the immunologic mechanism. Overexpression of Th1 cytokines such as IFN-γ, TNF-α and IL-12 in lesions has been reported. Because TNF-α plays a key role in granuloma maintenance and macrophage activation, this provides the theoretical basis for the effectiveness of TNF inhibitors that block it. As a mechanism shared with Crohn disease, there may be a common pathway in which intestinal mucosal immune abnormalities (NOD2 pathway, impaired barrier function) cause extraintestinal granulomatous disease.
Angioneurotic factors have also been proposed. The hypothesis is that autonomic dysfunction increases vascular permeability, contributing to initial edema, and that subsequent repeated edema and lymphatic damage lead to persistent edema and fibrosis. Early episodes can be difficult to distinguish from angioedema. The hypothesis that changes in the oral microbiota trigger mucosal immune abnormalities is also being explored recently.
The three cardinal clinical symptoms of MRS are recurrent facial palsy (facial nerve palsy), orofacial edema and fissured tongue (plicated tongue). However, the complete triad appears in only about 25% of all cases; the rest are monosymptomatic or oligosymptomatic forms. The most common single symptom is lip enlargement, which is sometimes separately called cheilitis granulomatosa of Miescher.
Orofacial edema develops suddenly and at first resolves spontaneously, but with repetition becomes fixed as persistent, irreversible enlargement. It mainly involves the upper lip, and the lower lip, cheeks, orbits, forehead, scalp and limbs (hands, feet, etc.) can also be involved. The edema is characterized by a non-pitting, elastic texture, and the skin over the swollen area is normal or erythematous. Edema of the oral mucosa, gums, palate and buccal mucosa may also occur, accompanied by limited mouth opening, speech abnormalities and dysphagia.
The facial nerve palsy has the same clinical findings as Bell palsy and is a peripheral palsy involving both the upper and lower facial muscles. Unilateral involvement is most common, but alternating or bilateral involvement also occurs. Recurrence is an important feature of MRS, and recovery after each episode becomes incomplete, so function is cumulatively impaired. The first episode mostly recovers completely, but with 3 or more recurrences the risk of permanent palsy increases.
Fissured tongue is the formation of deep longitudinal or transverse grooves (fissures) on the tongue surface and is often asymptomatic. Because it is an anatomic variant present in 5–11% of the general population, MRS cannot be diagnosed by fissured tongue alone. Taste abnormalities, idiopathic loss of taste (ageusia), ear pain, hearing abnormalities and facial sensory abnormalities due to trigeminal nerve involvement are rarely present.
On physical examination, the key sign of MRS is non-pitting, elastic lip enlargement. On palpation it is firm and elastic, and no indentation remains after pressure, distinguishing it from angioedema and inflammatory edema. A chronically affected lip appears as a "sausage lip." Upper lip involvement is more common than lower lip involvement, and deformity of the oral commissures may also occur.
Facial nerve palsy is graded with the standard House-Brackmann (HB) scale. Of HB grades I (normal) to VI (complete paralysis), grades II–V are most common, and loss of forehead wrinkles, inability to close the eye completely (lagophthalmos), loss of the nasolabial fold and drooping of the corner of the mouth are observed. With repeated episodes, signs of aberrant reinnervation such as synkinesis and crocodile tears may appear.
On tongue examination, fissured tongue is seen as a deep fissure pattern over all or part of the tongue surface. Examination of the oral mucosa may reveal additional lesions such as gingival enlargement, buccal mucosal edema and palatal vesicles. Skin examination may show periorbital edema, frontal edema and, rarely, limb edema. Cervical lymphadenopathy may be present.
On neurologic examination, nerve involvement in MRS is mostly limited to the facial nerve, but abducens nerve palsy, trigeminal sensory abnormalities, hearing loss due to auditory nerve involvement, dysphagia due to vagus nerve involvement and vestibular symptoms have rarely been reported. Such multiple nerve involvement requires chest CT and serum ACE testing, particularly to differentiate sarcoidosis. On fundus examination, uveitis may rarely be present.
Screening for MRS begins with systematically confirming the pattern of recurrence of combinations of recurrent facial nerve palsy, lip enlargement and fissured tongue in patients who have one or more of them. MRS cannot be confirmed by a single episode alone, but it is important to suspect it and follow up. MRS should be included in the differential diagnosis of every patient who presents with recurrent Bell palsy or unexplained lip enlargement.
Facial nerve function assessment is objectified by functional grading with the HB scale and electrophysiologic tests (electroneurography, ENoG; electromyography, EMG). EMG is particularly useful for predicting the degree of axonal injury and prognosis in patients with recurrent palsy. To characterize the edema, a history of angioedema (C1-esterase inhibitor deficiency) is checked, and allergy skin patch testing and IgE measurement are performed selectively.
History-taking for gastrointestinal symptoms (abdominal pain, bloody stools, diarrhea, weight loss) is essential to determine whether Crohn disease coexists. Because the association between MRS and inflammatory bowel disease has been established in long-term follow-up studies, one-time gastrointestinal screening at diagnosis is considered even in the absence of gastrointestinal symptoms. Serum C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and fecal calprotectin are also useful for screening.
To differentiate sarcoidosis, chest X-ray and measurement of serum ACE, calcium and urine calcium are recommended. Facial MRI (fat-suppressed contrast-enhanced T1, T2) is useful for evaluating facial nerve enhancement and surrounding soft tissue edema. Blood testing includes a basic panel of autoantibodies (ANA, anti-dsDNA, anti-Ro/La), ACE, CBC and liver function.
The clinical diagnosis of MRS is made when one or more of the triad — ① recurrent facial palsy, ② facial and lip edema, ③ fissured tongue — is confirmed and other causes are excluded. However, because most cases do not meet the complete triad, histopathologic confirmation is important. Histopathologic confirmation of non-caseating granulomas is the diagnostic standard.
Tissue biopsy is performed on the swollen lip or oral mucosa. Histologic findings include non-caseating granulomas (epithelioid cell granuloma without central necrosis), lymphocytic infiltration, histiocytes and, rarely, multinucleated giant cells. Lymphatic dilation, perivascular lymphocytic infiltration, edema and epidermal acanthosis are also present. Tuberculosis and fungal infection must be excluded with acid-fast (Ziehl-Neelsen) and PAS staining.
To exclude Crohn disease, colonoscopy and small bowel imaging (MR enterography or CT enterography) are performed when gastrointestinal symptoms are present or gastrointestinal screening is needed. Sarcoidosis is differentiated by chest CT, bronchoalveolar lavage, serum ACE measurement and, if necessary, lymph node biopsy. Conditions to be appropriately differentiated include angioedema (confirm C1-INH deficiency), cellulitis, contact dermatitis, Sjögren syndrome, lymphoma and tumors.
Facial nerve MRI (contrast-enhanced T1, STIR) is useful for confirming signal enhancement within the facial canal and granulomatous infiltration of adjacent soft tissue. When lesions are extensive or atypical, skull base MRI and CT are added to exclude tumors or multiple cranial nerve involvement. Electroneurography and electromyography are used to quantify the degree of facial nerve injury and predict prognosis.
Treatment of MRS aims at symptom control, and there is no established curative treatment. Because treatment response varies greatly between individuals and recurrence is common, a long-term management plan is needed. Treatment is approached in three separate aspects: facial nerve palsy episodes, lip enlargement and prevention of recurrence.
Acute treatment of facial nerve palsy follows Bell palsy treatment guidelines. Prednisolone (1 mg/kg/day or 60–80 mg/day, tapered after 1 week) is given within 72 hours of symptom onset, and combination with an antiviral (acyclovir or valacyclovir) is recommended. Artificial tears, eye patches and eye shields are used to prevent corneal exposure, along with ophthalmologic care.
The first-line treatment for lip enlargement and cheilitis granulomatosa is intralesional triamcinolone acetonide injection (10–40 mg/mL, at 1–3 month intervals). It effectively reduces lip edema and produces improvement in 50–80%. Systemic corticosteroids (prednisolone 40–60 mg/day, short-term) are used for rapid reduction of edema in acute episodes, but long-term systemic administration is limited by adverse effects.
Second-line agents are needed in refractory or recurrent MRS. Clofazimine (100–200 mg/day) is an antileprosy drug with evidence of effectiveness in cheilitis granulomatosa. Thalidomide has also been reported in small studies to improve lip enlargement. Cases have been reported in which the TNF inhibitors infliximab (3–5 mg/kg IV, at weeks 0, 2 and 6 and then every 8 weeks) or adalimumab were used effectively in refractory MRS regardless of whether Crohn disease coexists. Minocycline (100 mg/day), an antibiotic with anti-inflammatory effects, is also tried in some patients. When repeated recurrence and permanent lip enlargement are established, surgical cheiloplasty is considered for aesthetic and functional improvement.
MRS is not a fatal disease, but it follows a chronic relapsing course and has a considerable impact on quality of life. Facial nerve palsy mostly recovers completely in the first episode, but the degree of recovery gradually decreases with repeated episodes. With 3 or more recurrences, the risk of residual sequelae of aberrant reinnervation, such as permanent facial deformity, hemifacial spasm, crocodile tears (Frey syndrome) and synkinesis, increases.
Lip enlargement resolves completely at first, but once fibrosis progresses after repeated episodes, permanent irreversible enlargement becomes fixed. This leads to aesthetic and functional problems (limited mouth opening, speech and swallowing abnormalities). The psychological impact is also large, and reduced self-esteem, social isolation and depression due to facial deformity may occur.
Coexisting Crohn disease has important prognostic significance. Because the rate of subsequent Crohn disease in patients with MRS is higher than in the general population, prompt endoscopic evaluation is needed when gastrointestinal symptoms appear during long-term follow-up. When Crohn disease coexists, complications of Crohn disease itself (strictures, fistulas, surgery) also affect prognosis. Conversely, treatment of Crohn disease (biologics) sometimes has a dual effect of also improving MRS symptoms.
In patients who respond well to treatment, the interval between recurrences tends to lengthen and the intensity of episodes tends to decrease. Regular follow-up (at 3–6 month intervals) is needed to comprehensively monitor facial nerve function, lip changes, gastrointestinal symptoms and mental health.
Because the cause of MRS is unclear, primary prevention (prevention of onset) is currently not possible. However, by avoiding recurrence triggers and treating promptly at recurrence, secondary prevention (reducing the frequency and intensity of recurrence) and tertiary prevention (minimizing functional impairment) are possible. A multidisciplinary approach (neurology, otolaryngology, oral and maxillofacial surgery, gastroenterology, ophthalmology) is key to long-term management.
Avoiding known recurrence triggers is important. Influenza vaccination and hand hygiene are recommended to prevent upper respiratory infections. Because dental procedures (extraction, root canal treatment, etc.) may be associated with triggering MRS episodes, prophylactic steroid administration before dental procedures is considered on an individual basis. When contact allergy is confirmed, contact with the relevant food additives, metals and so on is avoided. Because extreme stress can trigger episodes, stress management and mental health support are provided in parallel.
In patients with coexisting Crohn disease, active treatment of the underlying Crohn disease helps suppress MRS recurrence. Cases have been reported in which MRS episodes also decrease in patients treated for Crohn disease with TNF inhibitors (infliximab, adalimumab). Surveillance for new-onset Crohn disease and active treatment in MRS therefore have preventive significance. For family members with a confirmed genetic predisposition, educating them to seek specialist care immediately upon early onset of lip edema or facial palsy increases the opportunity for early diagnosis and treatment.